Clinical Trial Update: Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Sonesitatug Vedotin with Capecitabine, with or without Rilvegostomig, in advanced or metastatic Claudin18.2-expressing gastric, GEJ, or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• Rilvegostomig (rilvegostomig)
• Sonesitatug Vedotin (sonesitatug vedotin)

Snippet

Sponsor: AstraZeneca | Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: RECRUITING